Compare EBF & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | PRTC |
|---|---|---|
| Founded | 1909 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.2M | 386.7M |
| IPO Year | N/A | N/A |
| Metric | EBF | PRTC |
|---|---|---|
| Price | $17.62 | $16.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 227.1K | 4.7K |
| Earning Date | 12-22-2025 | 08-28-2025 |
| Dividend Yield | ★ 5.68% | N/A |
| EPS Growth | ★ 3.59 | N/A |
| EPS | ★ 1.63 | 0.20 |
| Revenue | ★ $388,344,000.00 | $6,391,000.00 |
| Revenue This Year | $0.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.82 | ★ $7.87 |
| Revenue Growth | N/A | ★ 1265.60 |
| 52 Week Low | $16.30 | $13.30 |
| 52 Week High | $22.01 | $23.69 |
| Indicator | EBF | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 61.37 | 51.25 |
| Support Level | $16.51 | $16.42 |
| Resistance Level | $17.49 | $16.83 |
| Average True Range (ATR) | 0.33 | 0.31 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 99.23 | 58.99 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.